Abstract
PURPOSE:
Patients with Lynch syndrome are much more likely to have generally rare upper urinary tract urothelial carcinoma but not bladder urothelial carcinoma.
While the risk has been quantified, to our knowledge there is no
description of how this population of patients with Lynch syndrome and
upper urinary tract cancer differs from the general population with
upper urinary tract cancer.
MATERIALS AND METHODS:
We
obtained retrospective data on a cohort of patients with Lynch syndrome
from the Hereditary Cancer Center in Omaha, Nebraska and compared the
data to those on a control general population from western Sweden. These
data were supplemented by a new survey about exposure to known risk
factors.
RESULTS:
Of the patients with Lynch syndrome
91% had mutations in MSH2 rather than in MSH1 and
79% showed upper tract urothelial carcinoma
a mean of 15.85 years after prior Lynch syndrome-type cancer. Median
age at diagnosis was 62 years vs 70 in the general population (p
<0.0001). Only half of our patients had a significant smoking history
and the male-to-female ratio was 0.95.
Of patients with Lynch syndrome
51% had urothelial carcinoma in the ureter while it occurred in the renal pelvis in 65% of the general population (p = 0.0013). Similar numbers of
high grade tumors were found in the Lynch syndrome and general populations (88% and 74%, respectively, p = 0.1108).
CONCLUSIONS:
Upper
urinary tract tumors develop at a younger age and are more likely to be
in the ureter with an almost equal gender ratio in patients with Lynch
syndrome. It has high grade potential similar to that in the general population.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.